Visiongain Report Claims There is Huge Potential Within the $5.9bn Anti-Idiopathic Pulmonary Fibrosis Drugs MarketHomeMailNewsFinanceSportsEntertainmentSearchMobileMore...YAHOO_FINANCESearchSign inMailSign in to view your mailFinance HomeWatchlistsMy PortfolioScreenersPremiumMarketsIndustriesPersonal FinanceVideosNewsTechU.S. Markets closedS&P 5002,978.76-137.63(-4.42%)Dow 3025,766.64-1,190.95(-4.42%)Nasdaq8,566.48-414.29(-4.61%)Visiongain Report Claims There is Huge Potential Within the $5.9bn Anti-Idiopathic Pulmonary Fibrosis Drugs MarketPR NewswireJanuary 9, 2020ReblogShareTweetShareGlobal Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast to 2029Antifibrotics, Tyrosine Kinase Inhibitors, Anti-inflammatory Drugs, Immunosuppressants, Other MoA, Innovator DrugsLONDON, Jan. 9, 2020 /PRNewswire/ -- The global anti-idiopathic pulmonary fibrosis drugs market is expected to grow at a CAGR of 16.7% in the first half of the forecast period. In 2018, the anti-fibrotics held the largest market share (51%) followed by the tyrosine kinase inhibitors.Visiongain LogoMoreHow this report will benefit youRead on to discover how you can exploit the future business opportunities emerging in this sector.In this brand new 171-page report you will receive 69 tables and 97 figures– all unavailable elsewhere.The 171-page Visiongain report provides clear detailed insight into the global anti-idiopathic pulmonary fibrosis drugs market. Discover the key drivers and challenges affecting the market.By ordering and reading our brand-new report today you stay better informed and ready to act.To request sample pages from this report please contact Sara Peerun at sara.peerun@visiongain.com or refer to our website: https://www.visiongain.com/report/global-anti-idiopathic-pulmonary-fibrosis-drugs-market-forecast-to-2029/#download_sampe_div Report Scope• Global Anti-Idiopathic Pulmonary Fibrosis Drugs market forecasts to 2029• This report also breaks down the revenue forecast for the global anti-idiopathic pulmonary fibrosis drugs market by mechanism of action:• Antifibrotics• Tyrosine Kinase Inhibitors• Anti-inflammatory Drugs• Immunosuppressants• Other MoA• This report also breaks down the revenue forecast for the global anti-idiopathic pulmonary fibrosis drugs market by Innovator and Off-label drugs:• Innovator Drugs• Off-label Drugs• This report provides individual revenue forecasts to 2029 for these national markets:• US• Japan• EU5: Germany, France, the UK, Italy, Spain• Rest of World• This report provides individual revenue forecasts to 2029 for these marketed drugs:• Esbriet• Ofev• Our study gives qualitative analysis of the anti-idiopathic pulmonary fibrosis drugs market. It discusses:• Diagnosed Prevalence of Idiopathic Pulmonary Fibrosis in the G7 markets• Epidemiology of Idiopathic Pulmonary Fibrosis by disease severity• Epidemiology of Idiopathic Pulmonary Fibrosis by gender• Discussion on novel clinical molecules under development for the treatment of Idiopathic Pulmonary Fibrosis• Pricing and Reimbursement Overview on Ofev and Esbriet (by NICE, SMC, PBAC, CADTH, G-BA, HAS)• A SWOT Analysis on the anti-idiopathic pulmonary fibrosis drugs marketTo request a report overview of this report please contact Sara Peerun at sara.peerun@visiongain.com or refer to our website: https://www.visiongain.com/report/global-anti-idiopathic-pulmonary-fibrosis-drugs-market-forecast-to-2029/ Did you know that we also offer a report add-on service? Email sara.peerun@visiongain.com to discuss any customized research needs you may have.Companies covered in the report include: ActelionAfferent PharmaceuticalsAmerican Thoracic Society (ATS)Asahi Kasei PharmaAuspex PharmaceuticalsBellerophon TherapeuticsBiogen Idec.BMSBoehringer IngelheimCanadian Agency for Drugs and Technologies in Health (CADTH) (Canada)CurisEuropean CommissionEuropean Respiratory Society (ERS)FDAFibroGenGalapagosGalectoGenentechGlobal Blood TherapeuticsHaute Autorité de Santé (HAS) (France)IkariaIldong Pharmaceutical Co., Ltd.Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) (Germany)IntelGenXInterMuneJanssenJapanese Respiratory Society (JRS)Kadmon CorporationKadmon HoldingsKedem PharmaceuticalsKyorinLatin American Thoracic Association (ALAT)LTT Bio-PharmaMediciNovaMerckMicroDose TherapeutxMoerae MatrixNano TerraNational Institute for Health and Care Excellence (NICE)Nippon ShinyakuPacific TherapeuticsPharmaceutical Benefits Advisory Committee (PBAC) (Australia)PharmaxisPromediorProMetic Life SciencesQuintilesRocheSanofiScottish Medicines Consortium (SMC) (Scotland)Shionogi & Co., Ltd Stromedix Inc.SynairgenTevaZai LabStory continuesTo see a report overview please e-mail Sara Peerun on sara.peerun@visiongain.com Related reports:Biological Drug API Manufacturing Services World Industry and Market Forecast to 2029Global Biosimilars and Follow-On Biologics Market 2019-2029Top 25 Biosimilar Drug Manufacturers 2019Global Immunochemistry Reagents, Analyzers and Test Kits Market 2019-2029Biologics Market Trends and Forecasts 2019-2029CisionMoreView original content:http://www.prnewswire.com/news-releases/visiongain-report-claims-there-is-huge-potential-within-the-5-9bn-anti-idiopathic-pulmonary-fibrosis-drugs-market-300982847.htmlSOURCE VisiongainReblogShareTweetShareRecently ViewedYour list is empty.What to Read NextBiocontainment expert on coronavirus: There's no need for average people to panic yetYahoo FinanceA drug shortage due to the coronavirus is a 'considerable risk:' Fmr. FDA deputy commissionerYahoo Finance VideoStock market live updates: Dow drops 1190 points amid coronavirus fears, S&P 500 sees fastest correction in historyYahoo FinanceAmid coronavirus, bitcoin has fallen 6% this week to below $8,800Yahoo FinanceEl-Erian: The Fed will cut rates in March, if not beforeYahoo Finance VideoJapan's January factory output beats forecasts but slowdown expectedReuters'Stuck in no man’s land': A working mom details dealing with her sick child's student loan billYahoo FinanceDon’t buy the stock dip yet, says Goldman as it warns coronavirus will wipe out earnings growth this yearMarketWatchRichard Branson’s Wealth Falls to Earth as Virgin Galactic SputtersBloombergCoronavirus-induced stock selloff means IPO market is 'on holiday': veteran IPO analystYahoo FinanceMarket Watcher: Over six months we will see the markets higher Yahoo Finance VideoWoman Who Snorted 550 Times the Usual Dose of LSD Survives and Experiences Dramatic Pain ReliefPeopleMost face masks won’t protect you from the coronavirusYahoo FinanceStock market live updates: Stock futures climb after historic rout; coronavirus fears persistYahoo FinanceStock Market Live Updates: Stocks stretch to new records; United Steel plunges on layoffs, profit warningYahoo FinanceBeyond Meat beats on Q4 earnings, founder says 'we would be crazy not to invest in growth right now'Yahoo Finance